```html

Kernicterus: What You Need to Know

What is Kernicterus?

Kernicterus is a rare but serious form of brain damage that occurs when high levels of unconjugated bilirubin (a yellow pigment produced by the breakdown of red blood cells) cross the blood‑brain barrier and deposit in the basal ganglia and other brain structures. The condition is most commonly seen in newborns, especially those with severe jaundice that is left untreated. Because bilirubin is neurotoxic, the accumulation can lead to permanent neurological deficits, hearing loss, visual impairment, and in severe cases, death.

Historically, Kernicterus was a leading cause of infant mortality before effective screening and phototherapy became widespread. Today, it remains a medical emergency that is preventable with early detection and prompt treatment of neonatal hyperbilirubinemia.

Common Causes

While Kernicterus itself is a complication, several underlying conditions raise bilirubin levels enough to cause it. The most frequent causes include:

• Hemolytic disease of the newborn (HDN): Usually due to ABO or Rh incompatibility, leading to rapid red‑cell destruction.
• Breast‑milk jaundice: Excessive enterohepatic circulation of bilirubin in some breastfed infants.
• Physiologic newborn jaundice: Normal breakdown of fetal hemoglobin; risk rises if the infant is pre‑term or has other risk factors.
• Genetic enzyme deficiencies: e.g., G6PD deficiency, hereditary spherocytosis, or Crigler‑Najjar syndrome (type I & II).
• Sepsis or serious infection: Inflammatory processes impair bilirubin conjugation and excretion.
• Prematurity: Immature liver enzymes reduce the ability to conjugate bilirubin.
• Maternal diabetes or drug exposure: Can increase fetal red‑cell turnover or impair hepatic function.
• Underlying liver disease: Biliary atresia or neonatal hepatitis can obstruct bilirubin clearance.
• Medications that displace bilirubin from albumin: Certain antibiotics (e.g., sulfonamides) or aspirin‑containing products.
• Prolonged use of total parenteral nutrition (TPN): May increase unconjugated bilirubin levels.

Associated Symptoms

Before bilirubin reaches neurotoxic levels, most infants show signs of jaundice. Once Kernicterus develops, the following neurological and systemic findings may appear:

• Yellowing of the skin and sclera (often first noticed on the face and then spreading).
• Lethargy or poor feeding.
• High‑pitch, “cry‑like” vocalizations or excessive fussiness.
• Hypotonia (floppy limbs) progressing to hypertonia (rigidity) and “tight‑jaw” appearance.
• Opposite‑side (contralateral) seizures or focal seizures.
• Auditory dysfunction – diminished startle reflex or sensorineural hearing loss.
• Visual disturbances – poor tracking, nystagmus, or “sun‑setting” eyes.
• Movement disorders later in childhood (cerebral palsy‑like spasticity, dystonia).
• Developmental delays and intellectual impairment.

When to See a Doctor

Newborn jaundice often resolves without complications, but you should seek medical attention **immediately** if any of the following occur:

• Yellowing that spreads to the chest, abdomen, or limbs, especially within the first 24 hours of life.
• Change in the infant’s level of alertness – excessive sleepiness, difficulty waking, or irritability.
• Poor feeding or failure to gain weight.
• Vomiting, especially if it is green or contains blood.
• Any seizure‑like activity (jerking movements, staring spells).
• High‑pitched cry, difficulty sucking, or a “tight‑jaw” appearance.
• History of blood‑type incompatibility, family history of jaundice disorders, or prematurity.

If you are unsure, call your pediatrician or go to the nearest emergency department. Early intervention can prevent permanent injury.

Diagnosis

Diagnosis of Kernicterus involves confirming severe hyperbilirubinemia and assessing neurologic injury.

Laboratory Tests

• Total serum bilirubin (TSB): Serial measurements; levels >20 mg/dL (340 µmol/L) in term infants or >15 mg/dL (260 µmol/L) in preterm infants are alarming.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin: Kernicterus is linked to high unconjugated fractions.
• Complete blood count (CBC) and reticulocyte count – to detect hemolysis.
• Blood type and Coombs test – for immune‑mediated hemolysis.
• G6PD assay, liver function tests, and genetic panels when indicated.

Imaging & Neuro‑assessment

• Transcranial ultrasound: May reveal bright basal ganglia echo‑signals in acute kernicterus.
• Magnetic resonance imaging (MRI): T1‑weighted images show hyperintensity in the globus pallidus, putamen, subthalamic nuclei, and hippocampus.
• Auditory brainstem response (ABR) testing: Screens for early hearing loss.
• Standard neurologic exam – assessment of tone, reflexes, eye movements, and level of consciousness.

Clinical Scoring Systems

Many hospitals use the Bhutani nomogram (also called the “bilirubin hour‑specific chart”) to decide if phototherapy or exchange transfusion is required based on infant age and bilirubin level.

Treatment Options

The primary goal is to rapidly lower serum bilirubin and prevent further brain exposure.

Acute Medical Management

• Phototherapy: Blue‑light (460‑490 nm) converts bilirubin into water‑soluble isomers that can be excreted without conjugation. Intensive or double‑surface phototherapy is used for very high levels.
• Exchange transfusion: Indicated when bilirubin exceeds exchange thresholds (e.g., >25 mg/dL in term infants or when neurologic symptoms appear). Whole blood is removed and replaced with compatible donor blood, instantly lowering bilirubin.
• Intravenous Immunoglobulin (IVIG): May be given for immune‑mediated hemolysis (e.g., Rh incompatibility) to reduce hemolysis and the need for exchange transfusion.
• Albumin infusion: In selected cases, high‑dose albumin can bind free bilirubin, reducing its brain penetration (used when bilirubin is rising despite phototherapy).

Supportive & Long‑Term Care

• Monitoring of temperature, hydration, and electrolyte status.
• Feeding support – frequent breastfeeding, supplemental formula, or tube feeding if the infant cannot suck effectively.
• Hearing evaluation and early‑intervention services for children with auditory or developmental delays.
• Physical, occupational, and speech therapy for motor and cognitive deficits.
• Family counseling and genetic counseling when hereditary disorders are identified.

Home‑Based Measures (After Hospital Discharge)

• Continue regular bilirubin checks if the infant remains borderline.
• Ensure adequate feeding – aim for 8–12 feedings per 24 hours to promote bilirubin excretion.
• Expose the baby to indirect sunlight for short periods (10–15 minutes) if advised by a physician; natural light provides modest phototherapy but should never replace medical treatment.
• Track stool color; pale or acholic stools may indicate biliary obstruction and require prompt evaluation.

Prevention Tips

Most cases of kernicterus are preventable with vigilant prenatal and post‑natal care.

• Maternal blood‑type screening: Identify ABO/Rh incompatibility early and give RhIg (Rho(D) immune globulin) when indicated.
• Early bilirubin assessment: Obtain a serum bilirubin level before discharge for at‑risk newborns (premature, low birth weight, hemolytic disease, etc.).
• Encourage frequent feeding: Frequent milk intake speeds intestinal transit and reduces enterohepatic circulation of bilirubin.
• Avoid medications that displace bilirubin: Discuss any maternal or infant drug exposure with the pediatrician.
• Prompt treatment of neonatal jaundice: Initiate phototherapy according to established nomograms rather than waiting for “worsening” signs.
• Manage risk factors: Treat G6PD deficiency, monitor for sepsis, and correct any metabolic disturbances (e.g., hypoglycemia, acidosis) that can impair bilirubin clearance.
• Educate caregivers: Provide discharge instructions that emphasize when to seek care, how to monitor jaundice, and the importance of follow‑up appointments.

Emergency Warning Signs

Key Take‑aways

• Kernicterus is preventable brain damage caused by very high levels of unconjugated bilirubin.
• Prompt detection of neonatal jaundice and early use of phototherapy are the cornerstones of prevention.
• Risk factors include hemolytic disease, prematurity, genetic enzyme defects, and certain medications.
• Watch for warning signs such as spreading jaundice, poor feeding, extreme sleepiness, or seizures.
• Treatment may require phototherapy, exchange transfusion, and supportive care; long‑term follow‑up is essential for children who have been affected.

For the most current recommendations, consult trusted resources such as the Mayo Clinic, the Centers for Disease Control and Prevention, and the National Institutes of Health.

```